Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma.
作者信息
Raedler Lisa A
出版信息
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):140-3.
Abstract
摘要
相似文献
1
Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma.
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):140-3.
2
Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.
Clin Lymphoma Myeloma Leuk. 2023 Mar;23(3):e164-e170. doi: 10.1016/j.clml.2022.12.007. Epub 2022 Dec 9.
3
FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma.
Oncologist. 2018 Jun;23(6):734-739. doi: 10.1634/theoncologist.2017-0440. Epub 2018 Feb 7.
4
Lenalidomide in multiple myeloma.
Expert Rev Anticancer Ther. 2006 Aug;6(8):1165-73. doi: 10.1586/14737140.6.8.1165.
5
Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid capsule in healthy Chinese males.
Cancer Chemother Pharmacol. 2018 Jul;82(1):159-164. doi: 10.1007/s00280-018-3604-x. Epub 2018 Jun 11.
6
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma.
Ther Clin Risk Manag. 2008 Feb;4(1):129-36. doi: 10.2147/tcrm.s1445.
7
[Lenalidomid (Revlimid) in the treatment of multiple myeloma--first experience in the Czech Republic].
Cas Lek Cesk. 2008;147(12):623-6.
8
The paradoxical pharmacological mechanisms of lenalidomide and bortezomib in the treatment of multiple myeloma.
Anticancer Drugs. 2021 Mar 1;32(3):227-232. doi: 10.1097/CAD.0000000000001041.
9
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
Oncologist. 2008 Oct;13(10):1120-7. doi: 10.1634/theoncologist.2008-0077. Epub 2008 Oct 15.
10
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Blood. 2008 Feb 1;111(3):1101-9. doi: 10.1182/blood-2007-05-090258. Epub 2007 Nov 7.
引用本文的文献
1
Current State of Therapeutics for HTLV-1.
Viruses. 2024 Oct 15;16(10):1616. doi: 10.3390/v16101616.
2
Acute hypoxic respiratory failure due to Lenalidomide-induced interstitial pneumonitis in a patient with multiple myeloma.
BMC Pulm Med. 2024 Jul 4;24(1):321. doi: 10.1186/s12890-024-03129-z.
3
Multicolumn Nanoflow Liquid Chromatography with Accelerated Offline Gradient Generation for Robust and Sensitive Single-Cell Proteome Profiling.
Anal Chem. 2024 Jul 2;96(26):10534-10542. doi: 10.1021/acs.analchem.4c00878. Epub 2024 Jun 25.
4
Cancer drugs with high repositioning potential for Alzheimer's disease.
Expert Opin Emerg Drugs. 2023 Dec;28(4):311-332. doi: 10.1080/14728214.2023.2296079. Epub 2023 Dec 26.
5
A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment.
Cells. 2021 Oct 9;10(10):2700. doi: 10.3390/cells10102700.
6
Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q.
Cancers (Basel). 2021 Oct 11;13(20):5084. doi: 10.3390/cancers13205084.
7
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions.
Front Oncol. 2020 Jul 28;10:1243. doi: 10.3389/fonc.2020.01243. eCollection 2020.
8
Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology.
Medicina (Kaunas). 2019 Jul 28;55(8):414. doi: 10.3390/medicina55080414.
本文引用的文献
1
Multiple myeloma and physical activity: a scoping review.
BMJ Open. 2015 Nov 27;5(11):e009576. doi: 10.1136/bmjopen-2015-009576.
2
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551.
3
Multiple myeloma: the bone marrow microenvironment and its relation to treatment.
Br J Biomed Sci. 2013;70(3):110-20. doi: 10.1080/09674845.2013.11669945.
4
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.
Oncologist. 2013;18(1):27-36. doi: 10.1634/theoncologist.2011-0380. Epub 2013 Jan 8.
5
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
Oncologist. 2013;18(1):37-45. doi: 10.1634/theoncologist.2012-0113. Epub 2013 Jan 8.
6
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
N Engl J Med. 2007 Nov 22;357(21):2133-42. doi: 10.1056/NEJMoa070596.
7
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
N Engl J Med. 2007 Nov 22;357(21):2123-32. doi: 10.1056/NEJMoa070594.
8
Improved survival in multiple myeloma and the impact of novel therapies.
Blood. 2008 Mar 1;111(5):2516-20. doi: 10.1182/blood-2007-10-116129. Epub 2007 Nov 1.
Zotero 插件